CTLA4 and melanoma: demonstrated that PD-L1 on melanoma cells allowed tumors to escape anti-CTLA4-based therapy, and the combination of radiation, anti-CTLA4, and anti-PD-L1 promoted response and immunity through distinct mechanisms (100).